(Q50562489)

15 March 2018

title

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

1 reference

Erich Tauber

13

0 references

Stefan Zeuzem

10

object named as

Stefan Zeuzem

1 reference

15 March 2018

14

Michael P Manns

1 reference

15 March 2018

Heiner Wedemeyer

1

object named as

Heiner Wedemeyer

1 reference

15 March 2018

Holger Hinrichsen

12

object named as

Holger Hinrichsen

1 reference

15 March 2018

author name string

Elisabeth Schuller

2

1 reference

15 March 2018

Verena Schlaphoff

3

1 reference

15 March 2018

Rudolf E Stauber

4

1 reference

15 March 2018

Johannes Wiegand

5

1 reference

15 March 2018

Ingolf Schiefke

6

1 reference

15 March 2018

Christa Firbas

7

1 reference

15 March 2018

Bernd Jilma

8

1 reference

15 March 2018

Mark Thursz

9

1 reference

15 March 2018

Wolf P Hofmann

11

1 reference

15 March 2018

Christoph S Klade

15

1 reference

15 March 2018

language of work or name

English

0 references

publication date

24 June 2009

1 reference

15 March 2018

published in

Vaccine

1 reference

15 March 2018

volume

27

1 reference

15 March 2018

issue

37

1 reference

15 March 2018

page(s)

5142-5151

1 reference

15 March 2018

Replication of hepatitis C virus

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Global epidemiology of hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Natural history and predictors of disease severity in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

T cells and viral persistence: lessons from diverse infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Immunology of hepatitis B virus and hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Present and future therapy for hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Treating viral hepatitis C: efficacy, side effects, and complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Cellular immune selection with hepatitis C virus persistence in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Differences in Hepatitis C Virus (HCV)-Specific CD8 T-Cell Phenotype during Pegylated Alpha Interferon and Ribavirin Treatment Are Related to Response to Antiviral Therapy in Patients Chronically Infected with HCV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

The way forward in HCV treatment--finding the right path

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells Associated with Reversible Immune Dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

Dose sparing with intradermal injection of influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

New hepatitis B vaccine formulated with an improved adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.027

10.1016/J.VACCINE.2009.06.027

7 January 2021

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018